The peroxisome proliferator-activated receptor gamma system regulates ultraviolet B-induced prostaglandin e 2 production in human epidermal keratinocytes

PPAR Research

Volumn , Issue , 2010, Pages

  Konger, Raymond L ^a   Martel, Kellie Clay ^a   Jernigan, Danielle ^a   Zhang, Qiwei ^a   Travers, Jeffrey B ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROSTAGLANDIN E2; TERT BUTYL HYDROPEROXIDE;

ADULT; ARTICLE; BIOLOGY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; OXIDATIVE STRESS; PHOTOREACTIVITY; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; REGULATORY MECHANISM; ULTRAVIOLET B RADIATION;

EID: 77953511338     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/467053     Document Type: Article

References (40)

1. Kuenzli S., Saurat J.-H., Peroxisome proliferator-activated receptors in cutaneous biology British Journal of Dermatology 2003 149 2 229 236
2. Friedmann P. S., Cooper H. L., Healy E., Peroxisome proliferator- activated receptors and their relevance to dermatology Acta Dermato- Venereologica 2005 85 3 194 202
3. Michalik L., Wahli W., Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease Biochimica et Biophysica Acta 2007 1771 8 991 998
4. Zhang Q., Southall M. D., Mezsick S. M., Epidermal peroxisome proliferator-activated receptor as a target for ultraviolet B radiation The Journal of Biological Chemistry 2005 280 1 73 79
5. Zhang Q., Seltmann H., Zouboulis C. C., Konger R. L., Involvement of PPAR in oxidative stress-mediated prostaglandin E 2 production in SZ95 human sebaceous gland cells Journal of Investigative Dermatology 2006 126 1 42 48
6. Hsi L. C., Wilson L. C., Eling T. E., Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate: alteration in peroxisome proliferator-activated receptor The Journal of Biological Chemistry 2002 277 43 40549 40556
7. Davies S. S., Pontsler A. V., Marathe G. K., Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor ligands and agonists The Journal of Biological Chemistry 2001 276 19 16015 16023
8. He G., Thuillier P., Fischer S. M., Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPAR in normal mouse skin keratinocytes Journal of Investigative Dermatology 2004 123 6 1110 1119
9. Bae M.-A., Rhee H., Song B. J., Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines Toxicology Letters 2003 139 1 67 75
10. Baek S. J., Wilson L. C., Hsi L. C., Eling T. E., Troglitazone, a peroxisome proliferator-activated receptor (PPAR ) ligand, selectively induces the early growth response-1 gene independently of PPAR : a novel mechanism for its anti-tumorigenic activity The Journal of Biological Chemistry 2003 278 8 5845 5853
11. Leesnitzer L. M., Parks D. J., Bledsoe R. K., Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662 Biochemistry 2002 41 21 6640 6650
12. He G., Muga S., Thuillier P., Lubet R. A., Fischer S. M., The effect of PPAR ligands on UV- or chemically-induced carcinogenesis in mouse skin Molecular Carcinogenesis 2005 43 4 198 206
13. Nicol C. J., Yoon M., Ward J. M., PPAR influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis 2004 25 9 1747 1755
14. Indra A. K., Castaneda E., Antal M. C., Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor in epidermal keratinocytes Journal of Investigative Dermatology 2007 127 5 1250 1260
15. Konger R. L., Malaviya R., Pentland A. P., Growth regulation of primary human keratinocytes by prostaglandin E receptor EP 2 and EP 3 subtypes Biochimica et Biophysica Acta 1998 1401 2 221 234
16. Dickson M. A., Hahn W. C., Ino Y., Human keratinocytes that express hTERT and also bypass a p 16INK4a -enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics Molecular and Cellular Biology 2000 20 4 1436 1447
17. Duan S. Z., Ivashchenko C. Y., Russell M. W., Milstone D. S., Mortensen R. M., Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-activated receptor- both induce cardiac hypertrophy in mice Circulation Research 2005 97 4 372 379
18. ABI, Relative quantitation of gene expression. User Bulletin #2: ABI Prism 7700 Sequence Detection System, Applied Biosciences, 1997
19. Rivier M., Safonova I., Lebrun P., Griffiths C. E. M., Ailhaud G., Michel S., Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes Journal of Investigative Dermatology 1998 111 6 1116 1121
20. Westergaard M., Henningsen J., Svendsen M. L., Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid Journal of Investigative Dermatology 2001 116 5 702 712
21. Jiang Y. J., Kim P., Elias P. M., Feingold K. R., LXR and PPAR activators stimulate cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes Journal of Lipid Research 2005 46 12 2657 2666
22. He G., Sung Y. M., Fischer S. M., Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes Prostaglandins Leukotrienes and Essential Fatty Acids 2006 74 3 193 197
23. Pontsler A. V., St Hilaire A., Marathe G. K., Zimmerman G. A., McIntyre T. M., Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor and oxidized alkyl phospholipids from oxidized low density lipoprotein The Journal of Biological Chemistry 2002 277 15 13029 13036
24. Ashida M., Bito T., Budiyanto A., Ichihashi M., Ueda M., Involvement of EGF receptor activation in the induction of cyclooxygenase-2 in HaCaT keratinocytes after UVB Experimental Dermatology 2003 12 4 445 452
25. Thuillier P., Anchiraico G. J., Nickel K. P., Activators of peroxisome proliferator-activated receptor- partially inhibit mouse skin tumor promotion Molecular Carcinogenesis 2000 29 3 134 142
26. Mao-Qiang M., Fowler A. J., Schmuth M., Peroxisome-proliferator-activated receptor (PPAR)- activation stimulates keratinocyte differentiation Journal of Investigative Dermatology 2004 123 2 305 312
27. Konger R. L., Marathe G. K., Yao Y., Zhang Q., Travers J. B., Oxidized glycerophosphocholines as biologically active mediators for ultraviolet radiation-mediated effects Prostaglandins and Other Lipid Mediators 2008 87 14 1 8
28. Davies S. S., Pontsler A. V., Marathe G. K., Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor ligands and agonists The Journal of Biological Chemistry 2001 276 19 16015 16023
29. Nakamura Y., Kozuka M., Naniwa K., Arachidonic acid cascade inhibitors modulate phorbol ester-induced oxidative stress in female ICR mouse skin: differential roles of 5-lipoxygenase and cyclooxygenase-2 in leukocyte infiltration and activation Free Radical Biology and Medicine 2003 35 9 997 1007
30. Osakabe N., Yasuda A., Natsume M., Yoshikawa T., Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model Carcinogenesis 2004 25 4 549 557
31. Kuenzli S., Saurat J.-H., Peroxisome proliferator-activated receptors as new molecular targets in psoriasis Current Drug Targets: Inflammation Allergy 2004 3 2 205 211
32. Bachelez H., Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity Journal of Autoimmunity 2005 25 supplement 69 73
33. Rotsztejn H., Zalewska A., Trznadel-Budzko E., Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients: a pilot study Medical Science Monitor 2005 11 12 CR594 CR598
34. Genolet R., Wahli W., Michalik L., PPARs as drug targets to modulate inflammatory responses? Current Drug Targets: Inflammation Allergy 2004 3 4 361 375
35. Klotz L., Dani I., Edenhofer F., Peroxisome proliferator-activated receptor control of dendritic cell function contributes to development of CD4+ T cell anergy Journal of Immunology 2007 178 4 2122 2131
36. Bright J. J., Natarajan C., Muthian G., Barak Y., Evans R. M., Peroxisome proliferator-activated receptor- -deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis Journal of Immunology 2003 171 11 5743 5750
37. Fujimoto Y., Iwagaki H., Ozaki M., Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE 2 in rat skin transplant model International Immunopharmacology 2005 5 7-8 1131 1139
38. Gorman S., Tan J. W.-Y., Thomas J. A., Primary defect in UVB-induced systemic immunomodulation does not relate to immature or functionally impaired APCs in regional lymph nodes Journal of Immunology 2005 174 11 6677 6685
39. Pockaj B. A., Basu G. D., Pathangey L. B., Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E 2 secretion in patients with breast cancer Annals of Surgical Oncology 2004 11 3 328 339
40. Remy W., Sigl I., Leipold B., Prostaglandin E 2 gel improvement of psoriatic lesions International Journal of Dermatology 1986 25 4 266 268